Exposure to the mycotoxin deoxynivalenol reduces the transport of conjugated bile acids by intestinal Caco-2 cells

Jingxuan Wang1 · Wouter Bakker1 · Weijia Zheng1 · Laura de Haan1 · Ivonne M. C. M. Rietjens1 · Hans Bouwmeester1

Abstract
Conjugated bile acids are synthesized in liver and subsequently secreted into the intestinal lumen from which they are actively reabsorbed and transported back to liver. The efficient enterohepatic circulation of conjugated bile acids is important to maintain homeostasis. The mycotoxin deoxynivalenol (DON) is a fungal secondary metabolite that contaminates cereal food. Upon human exposure, it can cause intestinal dysfunction. We explored the effects of DON exposure on the intestinal absorption of conjugated bile acids and the expression of bile acid transporters using an in vitro model based on Caco-2 cell layers grown in transwells. Our study shows that the transport rate of taurocholic acid (TCA) is decreased after 48-h pre-exposure of the Caco-2 cells to 2 µM DON, which is a realistic intestinal DON concentration. Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter α (OSTα), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes. In addition, the transport of ten taurine or glycine-conjugated bile acids in a physiological relevant mixture by the intestinal Caco-2 cell layers was decreased after pre-exposure of the cells to DON, pointing at a potential for DON-mediated accumulation of the conjugated bile acids at the intestinal luminal side. Together the results reveal that DON inhibits intestinal bile acid reabsorption by reducing the expression of bile acid transporters thereby affecting bile acid intestinal kinetics, leading to bile acid malabsorption in the intestine. Our study provides new insights into the hazards of DON exposure.

Keywords Deoxynivalenol · Bile acid reabsorption · Conjugated bile acids · Bile acid transporters

Introduction
Mycotoxins are toxic secondary metabolites produced by fungi that can contaminate cereal food commodities. Mycotoxin-contaminated food products pose a severe foodborne risk to human health worldwide. According to a study performed by the United Nations Food and Agriculture Organization (FAO), approximately 25% of the global food and feed that is produced annually is contaminated with mycotoxins (Boutrif and Canet 1998), which was confirmed more recently (Eskola et al. 2020). Among the various mycotoxins, the trichothece toxin deoxynivalenol (DON) is one of the most prevalent and hazardous ones (Mishra et al. 2020). Because of the chemical stability, DON does not degrade during food processing and, therefore, can end up in the finished food product as consumed (Maresca 2013; Pinton and Oswald 2014). DON is absorbed through the intestinal epithelium, mainly by paracellular diffusion and is known to cause a variety of effects in the body (EFSA 2017; Sergent et al. 2006). Animal studies have revealed that chronic exposure to low concentration of DON alters intestinal functions resulting in malnutrition, diarrhea, vomiting and intestinal inflammation (Liu et al. 2020; Vignal et al. 2018). Intestinal in vitro studies have revealed that DON reduces the intestinal epithelial barrier function by reducing the expression of tight junction proteins and apoptosis of enterocytes (Lucioli et al. 2013; Pinton et al. 2009). Emerging evidence suggests DON is able to reduce the downstream gene transcription of the FXR/RXR pathway in porcine jejuna explants based on a pan-genomic transcriptomic analysis (Pierron et al. 2016). The Farnesoid X Receptor (FXR) pathway has an important regulatory function in intestinal bile acid metabolism (Jia et al. 2018). This suggests that a
Differences between the past and the present are unimportant in the face of the individual's present actions.

Bile acid homeostasis plays an important role in intestinal homeostasis. Primary bile acids are synthesized by hepatocytes and after conjugation with glycine (glyco-, G) or taurine (tauro-, T) secreted into bile. They subsequently are transported to the intestinal lumen where they are deconjugated and transformed into secondary bile acids by the intestinal microbiome (Jia et al. 2018). Thus, both conjugated and unconjugated bile acids can be found in the intestinal lumen, where most of the bile acids are taken up by intestinal epithelial cells and subsequently transported back to the liver. This enterohepatic circulation of bile acids is an extremely efficient process, with more than 90% of the intestinal bile acids being reabsorbed (Fromm and Kim 2010). Unconjugated bile acids can be reabsorbed by passive or facilitated absorption throughout all the small intestine segments, whereas conjugated bile acid is reabsorbed by active transport predominantly in the ileum. This active transport depends on the functioning of various bile acid transporters (Dawson et al. 2009). The apical sodium-dependent bile acid transporter (ASBT), ileal bile acid-binding protein (IBABP) and bile acid efflux transporters (i.e., the organic solute transporter (OST)) are the most important transporters (Dawson et al. 2009). These bile acid transporters can be regulated by multiple chemicals thus affecting the bile acid intestinal kinetics. It has been reported that these bile acid transporters are target genes of FXR, and regulated by FXR activity (Jia et al. 2018). Considering the effect of DON on FXR activity, we hypothesize that DON has the potential to induce bile acid malabsorption in the intestine by downregulating bile acid transporters.

The purpose of this study was to explore whether DON could reduce the intestinal reabsorption of bile acids and to study its potential mode of action using an in vitro testing strategy. To test our hypothesis, Caco-2 cell layers in transwells were pre-exposed to DON followed by exposure to bile acids to study their transport. Bile acid transport was quantified using an LC–MS/MS method, and intestinal barrier integrity was assessed by TEER measurements and Fluorescein paracellular transport marker evaluations. In addition, to investigate the mechanism underlying potential effects on the bile acid reabsorption, the mRNA expression of bile acid transporters was quantified following exposure of the cells to DON and/or FXR signaling pathway agonists.

Materials and methods

Cell culture

Human colon carcinoma Caco-2 cells (passage number 15–35) were grown at 37 °C with 5% CO₂ in Dulbecco Modified Eagle’s Medium (DMEM) GlutaMax™ (4.5 g/L n-glucose and pyruvate; Gibco BRL, Breda, The Netherlands), supplemented with 10% heat-inactivated fetal calf serum, 1% non-essential amino acid and 1% penicillin/streptomycin (Gibco BRL). Cells were subcultured at 60–70% confluence using 0.05% trypsin (Gibco BRL).

Cell viability

Caco-2 cells were seeded at 8 × 10⁶ cells/well in 96-well plate maintained in culture for 21 days, and the culture medium was used and changed every other day. Cytotoxicity of DON on the 21-day cultured Caco-2 cell layers was evaluated by the WST-1 assay. Briefly, 21-day cultured Caco-2 cells were exposed to 0–10 μM DON for 48 h, and subsequently, incubated with WST-1 reagents 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (Sigma-Aldrich, St. Louis, MO, USA). For this, WST was added at 10% of the medium volume and the absorbance was measured at 440 nm and 620 nm with a SpectraMax M2 microplate reader ( Molecular devices, San Jose, CA, USA) up to 60 min. Data were obtained by subtracting the 620 nm signal from the 440 nm signal. The cell viability was expressed as percentage of the control group.

In vitro intestinal Caco-2 cell layer barrier integrity

Caco-2 cells were seeded at 4 × 10⁴ cells/insert in 12-well polycarbonate membrane inserts with 0.4 μm pore size (Corning Costar, Schnelldorf, Germany) and maintained in culture for 21 days. The integrity of Caco-2 cell layers grown for 21 days was assessed using transepithelial electrical resistance (TEER) and Fluorescein transport measurements. Caco-2 cell layers were exposed to 0–10 μM DON for 48 h. The TEER was measured with Millicell® ERS-2 Electrical Volt-Ohm Meter (Millipore, Amsterdam, The Netherlands). TEER values were expressed as kΩ × cm². For fluorescein measurement, the exposure medium was removed by rinsing the cell layers with Hank’s balanced salt solution (Gibco BRL) supplemented with 10 mM HEPES (transport medium). After 30 min of incubation in transport medium, 25 nmol Fluorescein (Sigma-Aldrich) in 0.5 mL transport medium was added to the apical cell compartment. After 1 h of incubation, the amount of fluorescein was measured in the basal compartment with SpectraMax M2 microplate reader. The excitation and emission wavelengths were 490 and 520 nm, respectively. The data are presented as the percentage of control group.

Taurocholic acid (TCA) transport assay

Caco-2 cell layers grown in transwells for 21 days were exposed to 2 μM DON for 48 h. Then, the exposure medium was removed and the cell layers were gently rinsed with
transport medium. After 30 min incubation in transport medium, 2.5 nmol TCA (Sigma-Aldrich) in 0.5 mL transport medium was added to the apical compartment. After 0–180 min incubation, the amount of TCA was measured in the basal compartment using LC/MS/MS.

**Mixed conjugated bile acids’ transport assay**

Caco-2 cell layers grown in transwells for 21 days were exposed to 2 μM DON for 48 h. Then, the exposure medium was removed and the cell layers were gently rinsed with transport medium. After 30 min incubation in transport medium, 25 nmol mixed conjugated bile acids in 0.5 mL transport medium was added to the apical compartment. In the bile acid mixture, conjugated bile acids were present in the same ratio as in human serum (Bathena et al. 2013). In the mixture GCDCA, GCA, GDCA, TCDCA, TCA, GUDCA, TDCA, GLCA, TUDCA and TLCA were present in the following concentrations: 16.5, 9.5, 8.0, 6.5, 3.5, 3, 2.5, 0.3, 0.2 and 0.05 μM, respectively. After 0–180 min incubation, the amount of each conjugated bile acid was measured in the basal compartment using LC/MS/MS.

**Profiling of bile acids by LC/MS/MS**

Chromatographic separation of bile acids was carried out using the Shimadzu 8045 System (Kyoto, Japan). Aliquots of samples (1 μL) were injected by autosampler, and the analytes were separated on Phenomenex AJO-8782 as a guard column and Phenomenex 00B-4475-AN (50 mm × 2.1 mm × 1.7 μm × 100 Å, Kinetex C18) was used as an analytical column at a column temperature of 50 °C. The mobile phase consisted of MilliQ water with 0.01% formic acid (A) and methanol with 50% acetonitrile (B) using a starting gradient 30% B, 70% B at 7.5 min, 98% B at 7.6–10.0 min, and then immediate reduction to 30% B at 10.5–16 min with re-equilibration before the next injection. The flow rate was 0.65 mL/min. The optimal ESI source parameters were as follows: nebulizer gas, 3 L/min; heating gas and drying gas, 10 L/min; interface temperature, desolvation line (DL) temperature and heat block temperature were maintained 300 °C, 250 °C and 400 °C, respectively. The multiple reaction monitoring (MRM) and selective ion monitoring (SIM) modes were employed for quantification. Data were collected and processed using the LabSolutions software (Shimadzu). The chromatogram of bile acid profiling and quantification table is provided in Supplementary materials Fig. S1 and Table S1.

**mRNA extraction and RT-qPCR analysis**

21-day cultured Caco-2 cell layers were exposed to 2 μM DON or 2 μM synthetic FXR ligand GW4064 (Sigma-Aldrich) for 48 h depending on the experiment. RNA was isolated using the QIAshredder and RNeasy® mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The quantity and quality of isolated mRNA were confirmed by Nanodrop (ND-1000; ThermoScientific, Waltham, MA, USA). Subsequently, cDNA was generated from 300 ng of total RNA using the QuantiTect® reverse transcription kit (Qiagen). RT-qPCR analysis was carried out using the Rotor-Gene® SYBR® Green PCR kit and the Rotor-Gene® 6000 cycler according to the manufacturer’s handbook. The human-specific primers we used were commercially available QuantiTect® primer assays, including OSTα, IBABP, ASBT and β-actin. The FXR primer (Biolegio, Nijmegen, The Netherlands) was synthesized according to the sequence (F:-CTCACAGATTTCAGACTTGGAC , R:GAACATAGCTTCAAACCGAGAC). The efficiency of the primers was checked prior to sample measurement. Values were quantified using the comparative threshold cycle method and target gene mRNA expression was normalized to β-actin (Pfaffl et al. 2001). The data are presented as percentage of control group.

**Statistics**

Data are presented as the means of three biological replicates ± SD. Statistical analysis was performed by Student t test or ANOVA followed by the Duncan test. p < 0.05 was considered as statistically significant. All data were analyzed with SPSS Version 17.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**DON reduces the integrity of Caco-2 cell layer**

For our studies, we needed to select a concentration of DON that does not affect the viability of 21-day cultured Caco-2 cell layers (viability of pre-confluent Caco-2 cells exposed to DON is shown in supplementary Fig. S2). We, therefore, exposed 21-day cultured Caco-2 cell layers to increasing concentrations of DON (0–10 µM) for 48 h. Mitochondrial activity in the 21-day cultured Caco-2 cells, as measured by the WST-1 assay, was not affected by the DON concentrations tested (Fig. 1A). In addition, we assessed whether exposure to DON disrupted the barrier properties of 21-day cultured Caco-2 cell layers. For this, we assessed the effect of DON on TEER and paracellular fluorescein translocation. Only DON concentrations of 5 and 10 µM affected the integrity of the Caco-2 cell layers as can be seen from the reduction of TEER values (less than 33.54 ± 0.35%) and the increase in fluorescein permeation (more than 450.92 ± 15.73%) compared to control group (Fig. 1B and C). Exposure of Caco-2 cell layers to 2.5 µM DON and
lower concentrations did neither alter the cell layer barrier properties nor did it reduce the cell viability. Based on these results, we selected a DON concentration of 2 µM for the subsequent studies.

**DON decreases the TCA active transport across a Caco-2 cell layer**

As tauro-conjugated bile acid, TCA is reabsorbed by intestinal bile acid transporters in the terminal ileum (Dawson and Karpen 2015). To assess the effect of DON on TCA active transport across Caco-2 cell layers, 21-day cultured cell layers were pre-incubated with 2 µM DON for 48 h. This concentration of DON was shown to be non-toxic. Following DON pre-exposure, the Caco-2 cell layers were incubated with 2.5 nmol TCA in 0.5 mL transport medium in the apical compartment for 180 min. TCA could not be detected in the basal compartment during 180 min transport when the transport experiment was performed at 4 °C (with or without DON pre-incubation). However, at 37 °C, TCA transport was significantly reduced following DON pre-exposure, the rates of TCA transport were 0.021 and 0.032 pmol/10³ cells per min with or without DON pre-exposure, respectively (Fig. 2).

**DON downregulates the mRNA expression of bile acid transporters in Caco-2 cell layers**

TCA can be transported from the intestinal lumen into the enterocyte by the apical sodium-dependent bile acid transporter (ASBT). In the cytoplasm of the enterocyte, TCA binds to the ileal bile acid-binding protein (IBABP) and is subsequently presented to the organic solute transporter (OST) that is present in the basal membrane via which it will be excreted (Meier and Stieger 2002). To explore the mechanism of the DON-induced decrease of TCA transport across the Caco-2 cell layers, the mRNA expression of bile acid transporters was analyzed by RT-qPCR. As shown in Fig. 3, the mRNA expression of the OSTα, IBABP and ASBT was decreased to 16.28 ± 16.55%, 36.22 ± 23.14% and 53.99 ± 12.42% compared to the control group, respectively, after exposure to 2 µM DON for 48 h.
The gene expression of bile acid transporters can be influenced by FXR, which is a member of the nuclear receptor superfamily of ligand-activated transcription factors (Jia et al. 2018; Wang et al. 2008). Exposure of the 21-day cultured Caco-2 cells to DON did not affect the FXR gene expression itself (Fig. S3). However, following exposure to the FXR agonist GW4064, the mRNA expression of OSTα and IBABP increased significantly, i.e., 4.17 ± 2.14 and 113.50 ± 77.37 times, respectively, compared with the control (Fig. 4A and B). For ASBT, the expression increased 1.83 ± 0.85 times compared with the control (N.S.) following exposure to the FXR agonist GW4064. This proves that OSTα and IBABP are downstream genes, regulated by FXR activity, while this cannot be concluded for ASBT since the effect of the FXR on the ASBT mRNA expression was not significant.

In line with the results presented in Fig. 3, exposure of the 21-day cultured Caco-2 cells to 2 µM DON decreased the mRNA expression of OSTα, IBABP and ASBT compared to the control. Exposure to DON also reduced the FXR agonist GW4064-mediated increase in the mRNA expression of the three transporters OSTα, IBABP and ASBT. The GW4064-mediated induction of OSTα and IBABP was no longer significant in the presence of DON while this DON-mediated reduction in GW4064-induced mRNA expression appeared significant especially in the case of ASBT mRNA (Fig. 4A–C).

**DON decreases the conjugated bile acid transport through Caco-2 cell layers**

Finally, we not only assessed the transport of one single bile acid (see Fig. 2), but assessed if exposure to DON affects the transport of the individual conjugated bile acids if Caco-2 cells are exposed to 50 µM conjugated bile acids (i.e., a physiological relevant mixture, see “Materials and methods” section for composition) (Bathena et al. 2013). As shown in Fig. 5A–J, the transport of all these ten conjugated bile acids decreased after DON pre-exposure and the same trend can also be seen in the transport upon exposure of the Caco-2 cells to higher concentrations of the mixture of conjugated bile acids (Fig. S4A and B). After 3-h transport, the amount of total conjugated bile acids in the upper compartment was 12.21 ± 0.65 and 22.00 ± 2.16 nmol without or with DON pre-exposure, respectively. In addition, the amount of total conjugated bile acids in the basal compartment was 12.72 ± 1.60 and 3.85 ± 1.04 nmol without or with DON pre-exposure, respectively (Fig. 5K). The results indicated that the total conjugated bile acid transport through Caco-2 cell layer decreased significantly which results in a higher remaining concentration in the apical compartment after pre-exposure with the 2 µM DON. However, the relative proportion of each conjugated bile acid in the total bile acid after transport was not much different comparing the results with or without pre-exposure to DON. GCDC and GCA were the most abundant ones remaining in the upper compartment, with amounts that increased from 2.85 ± 0.21 to 5.60 ± 1.13 nmol and 3.61 ± 0.28 to 5.50 ± 0.36 nmol after pre-exposure to DON.

**Discussion**

In this study, we demonstrated that exposure to the mycotoxin deoxynivalenol (DON) reduced the active transport of conjugated bile acids across Caco-2 cell layers and
decreased the expression of bile acid transporters OSTα, IBABP and ASBT in the cells. In addition, DON counteracted the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes pointing at the involvement of the FXR pathways in this DON-mediated effect on bile acid transporters and transport.

Human exposure to DON has long been associated with intestinal dysfunction (Maresca and Fantini 2010). To protect the consumer from the adverse health effects of DON, the European Food Safety Authority (EFSA) established a TDI of 1 µg/kg bw based on a reduced body weight gain in mice (EFSA 2017). Based on this, the permissible level
of DON in cereal flours for direct human consumption is 750 μg/kg in the European Union (EFSA 2017), and 1000 μg/kg in the United States (EFSA 2017; Mishra et al. 2020). We aimed to use a realistic DON concentration in our in vitro studies. Assuming that maximal tolerated DON levels are present and ingested in one meal, and that upon ingestion this is diluted in 1 L of gastrointestinal fluid and is totally bio-accessible, an intestinal lumen concentration of 2.5–3.3 μM DON can be estimated (EFSA 2017; Mishra et al. 2020).

Exposure of 21-day cultured Caco-2 cell layers to 2.5 μM DON and lower concentrations did neither alter the cell layer barrier properties nor did it reduce the cell viability, which was in agreement with previous studies on differentiated Caco-2 cell layers (Bony et al. 2006; Wang et al. 2019). However pre-exposure to 2 μM DON decreased the amount of TCA transported across the Caco-2 cell layers. TCA has long been used as a model bile acid for the study of bile acid active transport (Heubi et al. 1982; Li et al. 2018). In vivo, decreased bile acid active transport may lead to disturbance of bile acid homeostasis, as most of the bile acid pool in human intestine is conjugated to taurine or glycine metabolites. Their active uptake across the apical brush border membrane and the basal membrane requires the presence of ileal transporters (Northfield and McColl 1973). Therefore, we subsequently studied the expression and the regulation thereof of the ileal ASBT mediates the initial uptake of bile acids across the ileal enterocyte apical brush border membrane, only a small fraction of the taurine or glycine bile acid metabolites escapes absorption and is excreted in the feces (Li et al. 2018). In our study, the mRNA expression of ASBT was decreased following DON exposure. It has been reported previously that a downregulation of ASBT is related to the decrease of TCA influx into differentiated Caco-2 cells (Thomas et al. 2006). In addition, clinical research found that mutations of the ASBT gene are associated with primary bile acid malabsorption (Oelkers et al. 1982; Li et al. 2018). In vivo, decreased bile acid active transport may lead to disturbance of bile acid homeostasis, as most of the bile acid pool in human intestine is conjugated to taurine or glycine metabolites. Their active uptake across the apical brush border membrane and the basal membrane requires the presence of ileal transporters (Northfield and McColl 1973).

In our study, the mRNA expression of OSTα and IBABP was increased following exposure to the FXR agonist GW4064 which proved that OSTα and IBABP are downstream genes, regulated by FXR activity. This corroborates earlier observations in which it has been reported that the FXR agonists GW4064 induced OST expression and the effect was blocked by FXR siRNA in Huh7 cells (Landrier et al. 2006). The GW4064-mediated induction of OSTα and IBABP was no longer significant in the presence of DON, indicating that DON could counteract the agonist activity of GW4064 on these genes. IBABP gene expression is transcriptionally activated by FXR through an FXR-responsive element in the IBABP promoter (Campana et al. 2005). It has also been reported that a decreased activity of FXR was associated with a reduction of IBABP expression in intestinal epithelial HT-29 cells in vitro (Gadala et al. 2011). The regulation of the ASBT expression by the FXR is controversial. In our study, for the gene expression of ASBT the effect of the FXR agonist was less strong as for OST and IBABP, with a non-significant increase up to 183 ± 85% of the control. This effect of the FXR agonist was fully prevented upon co-exposure with DON, since co-exposure to the FXR agonist and DON resulted in a similar reduction of ASBT expression as what was observed with DON alone. It has been reported that GW4064 increased the ASBT expression in ileum of rats and enhanced bile acid reabsorption, making it potential candidate for the treatment of bile acid malabsorption (Cao et al. 2019). Together, DON can not only cause bile acid malabsorption, but also counteracts the agonist activity of IBABP protects the enterocyte from the cytotoxic properties of bile acids (D’Onofrio et al. 2017). Decreased IBABP might suggest a risk of bile acid cytotoxicity in the cytoplasm following DON exposure potentially contributing to impaired integrity of the barrier function. Lastly, the basolateral membrane transporter OSTα is important for exporting conjugated bile acids from the enterocyte into the portal circulation. In our study, the mRNA expression of OSTα was decreased following DON exposure. It has been reported that a reduced ileal expression of OSTα led to low ileal bile acid reabsorption (Renner et al. 2008). After transferring the human OST gene into the MDCK cell, the uptake of TCA by the OST/MDCKII cell was significantly increased, which indicated the important role of OST in bile acid transport (Suga et al. 2019).

The expression of bile acid transporters is regulated via nuclear receptors. The FXR is a member of the superfamily of nuclear receptors and mainly expressed in the ileum and liver. Once activated, it binds to the FXR-responsive elements on the promoters of target genes and regulates the transcription of target genes involved in bile acid synthesis, transport and metabolism. Both IBABP and OST have been reported as target genes of FXR (Jia et al. 2018). In our study, the mRNA expression of OSTα and IBABP was increased following exposure to the FXR agonist GW4064 and DON resulted in a similar reduction of ASBT expression as what was observed with DON alone. It has been reported that GW4064 increased the ASBT expression in ileum of rats and enhanced bile acid reabsorption, making it potential candidate for the treatment of bile acid malabsorption (Cao et al. 2019). Together, DON can not only cause bile acid malabsorption, but also counteracts the agonist activity of IBABP.
GW4064 on bile acid transporter genes, which increases the hazard of DON exposure on bile acid malabsorption.

Experiments with FXR-null mice suggested that the ASBT expression could also be downregulated through a pathway independent of FXR (Miyata et al. 2009). Alternatively to the FXR pathway regulation of ASBT expression via the c-Fos pathway has been postulated. c-Fos is a critical mediator of the repression of ASBT expression (Neimark et al. 2006). c-Fos phosphorylation results in an activation and translocation from cytoplasm to the nucleus where it forms a heterodimer with c-Jun which binds to dAP-1. This dAP-1/protein complex prevents the bile acid transporter ASBT transcription (Chen et al. 2002). It has been reported that DON induced the DNA-binding activities of c-Fos/c-jun in Raw 264.7 macrophage cells (Wong et al. 2002). Taken together, it may be concluded that DON might also regulate the ASBT expression via c-Fos pathway. Besides, DON is known to target the ribosome and inhibits the chain elongation step of protein synthesis, leading to an inhibition of RNA, DNA and protein synthesis (EFSA 2017; de Loubresse et al. 2014; Pestka 2010). The direct induction of the ribotoxic stress by DON will not only affect the downregulation of ASBT, but also that of OSTα, IBABP. This remains an interesting topic for future research.

We lastly evaluated the consequence of a reduced expression of the bile acid transporters on the uptake and transport of a physiological relevant mixture of taurine and glycine-conjugated bile acids. The transport of conjugated bile acids by the intestinal Caco-2 cell layer was decreased after pre-exposure of the cells to DON, which resulted in a higher remaining concentration of conjugated bile acids in the upper compartment. If extrapolated to the in vivo situation, this would lead to increased levels of taurine and glycine-conjugated bile acids in the terminal ileum. The conjugated bile acids which are not reabsorbed at the terminal ileum will continue to move with the intestinal contents to reach the colon and undergo transformations such as deconjugation, oxidation and epimerization by gut bacteria (Jia et al. 2018). There is considerable evidence that bile acids can modify colonic motility, ultimately leading to diarrhea and dysfunction of absorption in the intestine (Bajor et al. 2010). In our study, after exposure to a realistic ratio of mixed conjugated bile acids, the relative proportion of each conjugated bile acid in the total bile acid after transport was not much different comparing the results with or without pre-exposure to DON. GCDDCA and GCA are still the most abundant ones in the mixture remaining in the upper compartment following pre-exposure to DON, which can be deconjugated to CDCA and CA in the colon. CA and CDCA affected folding of different subsets of bacterial proteins, showing antibacterial function and reducing the diversity of gut microbiota (Dawson and Karpen 2015). Glycine, CA and TCA are well known to facilitate in vitro growth of Clostridium difficile, a pathogen responsible for significant morbidity of IBD and mortality in patients (Rupnik et al. 2009; Sorg and Sonenshein 2008). CA can be converted to DCA by bacterial dihydroxylation, which, combined with DCA formation via deconjugating of GDCA and TDCA, may result in a bile acid pool with more DCA that is more hydrophobic and toxic (Ridlon et al. 2006). It has been reported that excessive DCA in the intestinal lumen increased rabbit intestinal permeability (Fasano et al. 1990). The increase of intestinal permeability is a characteristic of intestinal dysfunction, including inflammation intestinal disease where it contributes to propagation and exacerbation of inflammation.

Conclusion

Our study shows that DON decreases the active transport of conjugated bile acids in a Caco-2 cell layer. DON down-regulates the expression of the bile acid transporters ASBT, IBABP and OSTα, and counteracts the agonist activity of the FXR agonist GW4064 on these genes. The decrease of the bile acid transporters can be expected to induce the malabsorption of conjugated bile acids in the intestine. Overall, it is concluded that DON affects the expression of the bile acid transporters and thereby bile acid intestinal kinetics, which provides new insights into the hazards of DON exposure.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00204-022-03256-8.

Acknowledgements The authors gratefully acknowledge prof.dr.ir. Jacques Vervoort for optimizing the LC–MS methods for the quantification of bile acids. This work was supported by a grant from the China Scholarship Council (No. 201906350086) to Jingxuan Wang.

Author contributions JW, LH, and HB contributed to the study conception and design. WB and WZ contributed to optimize the LC–MS method for the quantification of bile acids. This work was supported by a grant from the China Scholarship Council (No. 201906350086). JW conducted all the experimental work. Writing—original draft preparation: JW and HB; reviewing and editing: JW, HB and IR.

Funding This work was funded by China Scholarship Council (Grant no. 201906350086).

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
References

Bajor A, Gillberg P-G, Abrahamsson H (2010) Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 45(6):645–664

Bathena SPR, Mukherjee S, Olivera M, Alnouti Y (2013) The profile of bile acids and their sulfate metabolites in human urine and serum. J Chromatogr B 942:53–62

Bony S, Carcelen M, Olivier L, Devaux A (2006) Genotoxicity assessment of deoxynivalenol in the Caco-2 cell line model using the Comet assay. Toxicol Lett 166(1):67–76

Boutrif E, Canet C (1998) Mycotoxin prevention and control: FAO programmes. Revue de Medecine Veterinaire (France)

Campana G, Pasini P, Roda A, Spampinato S (2005) Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem pharmacol 69(12):1755–1763

Cao Y, Xiao Y, Zhou K et al (2019) FXR agonist GW4064 improves bile acid transport by primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter. Gastroenterology 131(2):554–567

Chen F, Lin M, Sartor RB et al (2002) Inflammatory-mediated repression of the ileal sodium-dependent bile acid transporter by f-cfos nuclear translocation. Gastroenterology 123(6):2005–2016

D’Onofrio M, Zanzoni S, Munari F, Monaco HL, Assalaf M, Capaldi S (2017) The long variant of human ileal bile acid-binding protein associated with colorectal cancer exhibits sub-cellular localization and lipid binding behaviour distinct from those of the common isoform. Biochimica Et Biophysica Acta (BBA)-General Subjects 1861(9):2315–2324

Dawson PA, Karpen SJ (2015) Intestinal transport and metabolism of bile acids. J Lipid Res 56(6):1085–1099

Dawson PA, Lan T, Rao A (2009) Bile acid transporters. J Lipid Res 50(12):2340–2357

de Loubresse NG, Prokhorova I, Holtkamp W, Rodchina MV, Yusupova G, Yusupov M (2014) Structural basis for the inhibition of the eukaryotic ribosome. Nature 513(7519):517–522

EFSA Panel on Contaminants in the Food Chain (CONTAM), Knutsen HK, Alexander J et al (2017) Risks to human and animal health related to the presence of deoxynivalenol and its acetylated and modified forms in food and feed. EFSA J 15(9):e04718

Eskola M, Kos G, Elliott CT, Hajšlová J, Mayar S, Kraka R (2020) Worldwide contamination of food-crops with mycotoxins: validity of the widely cited ‘FAO estimate’ of 25%. Crit Rev Food Sci Nutr 60(16):2773–2789

Fasano A, Budillon G, Guandalini S et al (1990) Bile acids reversible effects on small intestinal permeability. Dig Dis Sci 35(7):801–808

Fromm MF, Kim RB (2010) Drug transporters, vol 201. Springer Science & Business Media, Berlin

Gadaleta RM, Oldenburg B, Willemsen EC et al (2011) Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kB signaling in the intestine. Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease 1812(8):851–858

Heubi JE, Balisteri WF, Fondacaro JD, Partin JC, Schubert WK (1982) Primary bile acid malabsorption: defective in vitro ileal active bile acid transport. Gastroenterology 83(4):804–811

Jia W, Xie G, Jia W (2018) Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 15(2):111

Kok T, Hulzebos CV, Wolters H et al (2003) Enterohepatic circulation of bile salts in Farnesoid X receptor-deficient mice efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 278(43):41930–41937

Kramer W, Gribig F, Gutjahr U et al (1993) Intestinal bile acid absorption. Na (+)-dependent bile acid transport activity in rabbit small intestine correlates with the coexpression of an integral 93-kDa and a peripheral 14-kDa bile acid-binding membrane protein along the duodenum-ileum axis. J Biol Chem 268(24):18035–18046

Landrier J-F, Eloranta JJ, Vavracka SR, Kullak-Ublick GA (2006) The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and-β genes. Am J Physiol-Gastrointest Liver Physiol 290(3):G476–G485

Li M, Vokral I, Evers B, de Graaf IA, de Jager MH, Groothuis GM (2018) Human and rat precision-cut intestinal slices as ex vivo models to study bile acid uptake by the apical sodium-dependent bile acid transporter. Eur J Pharm Sci 121:65–73

Lin MC, Kramer W, Wilson F (1990) Identification of cytosolic and microsomal bile acid-binding proteins in rat ileal enterocytes. J Biol Chem 265(25):14986–14995

Liu M, Zhang L, Chu X-H et al (2020) Effects of deoxynivalenol on the porcine growth performance and intestinal microbiota and potential remediation by a modified HSCAS binder. Food Chem Toxicol 141:111373

Lucili J, Pinton P, Callu P et al (2013) The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: interest of ex vivo models as an alternative to in vivo experiments. Toxicon 66:31–36

Maresca M (2013) From the gut to the brain: Journey and pathophysiological effects of the food-associated trichothecene mycotoxin deoxynivalenol. Toxins 5(4):784–820

Maresca M, Fantini J (2010) Some food-associated mycotoxins as potential risk factors in humans predisposed to chronic intestinal inflammatory diseases. Toxicon 56(3):282–294

Meier PJ, Steiger B (2002) Bile salt transporters. Annu Rev Physiol 64:635–661. https://doi.org/10.1146/annurev.physiol.64.082201.100300

Mishra S, Srivastava S, Dewangan J, Divakar A, Kumar Rath S (2020) Global occurrence of deoxynivalenol in food commodities and exposure risk assessment in humans in the last decade: a survey. Crit Rev Food Sci Nutr 60(8):1346–1374

Miyata M, Matsuda Y, Nomoto M et al (2009) Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption. Drug Metab Dispos 37(2):338–344

Neimark E, Chen F, Li X et al (2006) c-Fos is a critical mediator of inflammatory-mediated repression of the apical sodium-dependent bile acid transporter. Gastroenterology 131(2):554–567

Northfield T, McColl I (1973) Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut 14(7):513–518

Oekkers P, Kirby LC, Heubi JE, Dawson PA (1997) Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Investig 99(8):1880–1887

Pestka JJ (2010) Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance. Arch Toxicol 84(9):663–679

Pfaffl MW et al (2001) A new mathematical model for relative quantification in real-time RT–PCR. Nucl Acids Res 29(9):e45
Pierron A, Mimoun S, Murate LS et al (2016) Microbial biotransformation of DON: molecular basis for reduced toxicity. Sci Rep 6:29105

Pinton P, Oswald IP (2014) Effect of deoxynivalenol and other Type B trichothecenes on the intestine: a review. Toxins 6(5):1615–1643

Pinton P, Nougayrède J-P, Del Rio J-C et al (2009) The food contaminant deoxynivalenol, decreases intestinal barrier permeability and reduces claudin expression. Toxicol Appl Pharmacol 237(1):41–48

Renner O, Harsch S, Strohmeyer S, Stange EF (2008) Reduced ileal expression of OSTα-OSTβ in non-obese gallstone disease. J Lipid Res 49(9):2045–2054

Ridlon JM, Kang D-J, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47(2):241–259

Rupnik M, Wilcox MH, Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7(7):526–536

Sergent T, Parys M, Garsou S, Pussemier L, Schneider Y-J, Laron-delle Y (2006) Deoxynivalenol transport across human intestinal Caco-2 cells and its effects on cellular metabolism at realistic intestinal concentrations. Toxicol Lett 164(2):167–176

Sorg JA, Sonenshein AL (2008) Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190(7):2505–2512

Suga T, Yamaguchi H, Ogura J, Mano N (2019) Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β. Biochimica Et Biophysica Acta (BBA)-Biomembranes 1861(5):1023–1029

Thomas C, Landrier J-F, Gaillard D et al (2006) Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Gut 55(9):1321–1331

Vignal C, Djouina M, Pichavant M et al (2018) Chronic ingestion of deoxynivalenol at human dietary levels impairs intestinal homeostasis and gut microbiota in mice. Arch Toxicol 92(7):2327–2338

Wang Y-D, Chen W-D, Moore DD, Huang W (2008) FXR: a metabolic regulator and cell protector. Cell Res 18(11):1087–1095

Wang X, Li L, Zhang G (2019) Impact of deoxynivalenol and kaempferol on expression of tight junction proteins at different stages of Caco-2 cell proliferation and differentiation. RSC Adv 9(59):34607–34616

Wong S-S, Zhou H-R, Pestka JJ (2002) Effects of vomitoxin (deoxynivalenol) on the binding of transcription factors AP-1, NF-κB, and NF-IL6 in RAW 264.7 macrophage cells. J Toxicol Environ Health Part A 65(16):1161–1180

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.